Host: E. coli • AA: 134-239 • Tag: N-terminal GST • MW: 40.7 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

BRD9 bromodomain (human, recombinant)

Item No. 11509

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • Bromodomain-containing protein 9
Purity
≥95% estimated by SDS-PAGE
Source
Recombinant human N-terminal GST-tagged BRD9 bromodomain expressed in E. coli
Amino Acids
134-239
MW
40.7 kDa
Formulation (Request formulation change)
50 mM Tris, pH 7.5, with 500 mM sodium chloride, 5% glycerol, and 5 mM β-mercaptoethanol
Host
E. coli
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    Contact Sales for Price & Availability

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Bromodomain-containing protein 9 (BRD9) is a member of family IV bromodomains.1 It is composed of an N-terminal bromodomain that recognizes acetyl-, propionyl- and butyryllysine modifications on histones and a C-terminal DUF3512 domain, and is a component of the SWI/SNF chromatin remodeling complex.2,3 BRD9 is involved in transcriptional regulation, androgen receptor signaling, inflammation, viral defense, and homologous recombination.4,5,6,7 Inhibition of BRD9 by the small molecule I-BRD9 (Item No. 17749) or PROTAC dBRD9 (Item No. 45720) inhibits the proliferation of prostate cancer cells in vitro, and knockdown of BRD9 reduces tumor growth in an LNCaP prostate cancer mouse xenograft model.4 BRD9 mutations have been found in patients with Sézary syndrome, an aggressive form of cutaneous T cell lymphoma (CTCL).8

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lloyd, J.T., and Glass, K.C. Biological function and histone recognition of family IV bromodomain-containing proteins. J. Cell. Physiol. 233(3), 1877-1886 (2018).

    2. Flynn, E.M., Huang, O.W., Poy, F., et al. A subset of human bromodomains recognizes butyryllysine and crotonyllysine histone peptide modifications. Structure 23(10), 1801-1814 (2015).

    3. St. Pierre, R., and Kadoch, C. Mammalian SWI/SNF complexes in cancer: Emerging therapeutic opportunities. Curr. Opin. Genet. Dev. 42, 56-67 (2017).

    4. Alpsoy, A., Utturkar, S.M., Carter, B.C., et al. BRD9 is a critical regulator of androgen receptor signaling and prostate cancer progression. Cancer Res. 81(4), 820-833 (2021).

    5. Wang, L., Oh, T.G., Magida, J., et al. Bromodomain containing 9 (BRD9) regulates macrophage inflammatory responses by potentiating glucocorticoid receptor activity. Proc. Natl. Acad. Sci. USA 118(35), e2109517118 (2021).

    6. Börold, J., Eletto, D., Busnadiego, I., et al. BRD9 is a druggable component of interferon-stimulated gene expression and antiviral activity. EMBO Rep. 22(10), e52823 (2021).

    7. Zhou, Q., Huang, J., Zhang, C., et al. The bromodomain containing protein BRD-9 orchestrates RAD51-RAD54 complex formation and regulates homologous recombination-mediated repair. Nat. Commun. 11(1), 2639 (2020).

    8. da Silva Almeida, A.C., Abate, F., Khiabanian, H., et al. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nat. Genet. 47(12), 1465-1470 (2015).